The PARP Inhibitors market size is anticipated to increase in the study period due to a direct consequence of an increase in R&D activity in the 7MM. Additionally, the competitive landscape is relatively sparse and the regulatory pathway for approval will likely involve extensive clinical trials to demonstrate safety and efficacy.
DelveInsight’s PARP Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, emerging PARP Inhibitors, market share of individual therapies, and current and forecasted PARP Inhibitors market size from 2020 to 2034, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the PARP Inhibitors Market Report
As per DelveInsight’s analysis, the PARP Inhibitors market is anticipated to grow at a significant CAGR by 2034.
Leading PARP Inhibitors companies such as Clovis Oncology, Allarity Therapeutics, BeiGene, AstraZeneca, AtlasMedx, and others are developing novel PARP Inhibitors that can be available in the PARP Inhibitors market in the coming years.
Some of the key PARP Inhibitors include RUBRACA, Stenoparib, Pamiparib, LYNPARZA, AZD5305, AMXI-5001, and others.
Discover which therapies are expected to grab the PARP Inhibitors market share @ PARP Inhibitors Market Report
PARP Inhibitors Overview
PARP inhibitors are a class of drugs that inhibit the enzyme poly (ADP-ribose) polymerase (PARP). PARP enzymes play a critical role in repairing single-strand DNA breaks through the base excision repair pathway. When PARP is inhibited, single-strand breaks accumulate and lead to double-strand breaks during DNA replication. These double-strand breaks require homologous recombination for repair, a process dependent on the BRCA1 and BRCA2 genes.
PARP Inhibitors Treatment Market
LYNPARZA (olaparib) is a pioneering and leading oral poly ADP-PARP inhibitor, distinguished as the first targeted therapy to inhibit DDR in tumors with homologous recombination repair (HRR) deficiencies, such as BRCA1 and/or BRCA2 mutations. AstraZeneca collaborates globally with Merck to jointly develop and commercialize LYNPARZA.
ZEJULA (niraparib) is an oral, potent, and highly selective inhibitor of PARP1 and PARP2. PARP is a protein crucial for detecting and repairing DNA damage in cells, including damage caused by chemotherapy. As a PARP inhibitor, Niraparib prevents the repair of damaged DNA, leading to cell death. Cells with defects in the homologous recombination (HR) pathway, known as HRD cells, heavily depend on other repair proteins like PARP for survival.
RUBRACA (rucaparib) is an oral, small-molecule inhibitor of poly (ADP-ribose) polymerase (PARP) 1, 2, and 3, undergoing development for various tumor types such as ovarian and prostate cancers. It is explored both as monotherapy and in combination with other anti-cancer agents. Clovis possesses global rights for rucaparib. Presently, it has gained approval for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have responded completely or partially to platinum-based chemotherapy.
TALZENNA (talazoparib) is an oral inhibitor of poly ADP-ribose polymerase (PARP), involved in repairing DNA damage. Research before clinical trials has shown that TALZENNA hinders the activity of PARP enzymes and captures PARP at the DNA damage site, resulting in reduced growth of cancer cells and their eventual demise.
Learn more about the FDA-approved PARP Inhibitors @ PARP Inhibitors Drugs
Key PARP Inhibitors Therapies and Companies
RUBRACA: Clovis Oncology
Stenoparib: Allarity Therapeutics
Pamiparib: BeiGene
LYNPARZA: AstraZeneca
AZD5305: AstraZeneca
AMXI-5001: AtlasMedx
To know more about PARP Inhibitors clinical trials, visit @ PARP Inhibitors Treatment Drugs
PARP Inhibitors Market Dynamics
The PARP inhibitors market is experiencing significant growth driven by their effectiveness in treating cancers with specific genetic mutations, particularly BRCA1 and BRCA2. PARP inhibitors work by blocking the PARP enzyme, crucial for DNA repair in cancer cells, leading to cell death and reduced tumor growth. This mechanism is particularly beneficial for cancers that rely heavily on PARP due to defective homologous recombination repair pathways.
Key factors propelling the market include increased approval rates by regulatory authorities, expanding indications beyond ovarian and breast cancers to include prostate and pancreatic cancers, and growing awareness among healthcare providers and patients. Strategic collaborations and acquisitions among pharmaceutical companies are fostering innovation and broadening the scope of therapeutic applications.
However, challenges such as high treatment costs, potential side effects, and the development of resistance in some patients may temper market growth. Nevertheless, ongoing research and development activities aimed at improving efficacy and safety profiles are expected to sustain the market’s upward trajectory.
PARP Inhibitors Report Metrics
Details
Study Period
2020–2034
PARP Inhibitors Report Coverage
7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Key PARP Inhibitors Companies
Clovis Oncology, Allarity Therapeutics, BeiGene, AstraZeneca, AtlasMedx, and others
Key PARP Inhibitorss
RUBRACA, Stenoparib, Pamiparib, LYNPARZA, AZD5305, AMXI-5001, and others
Scope of the PARP Inhibitors Market Report
PARP Inhibitors Therapeutic Assessment: PARP Inhibitors current marketed and emerging therapies
PARP Inhibitors Market Dynamics: Attribute Analysis of Emerging PARP Inhibitors Drugs
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
PARP Inhibitors Unmet Needs, KOL’s views, Analyst’s views, PARP Inhibitors Market Access and Reimbursement
Discover more about PARP Inhibitors drugs in development @ PARP Inhibitors Clinical Trials
Table of Contents
1.
PARP Inhibitors Market Key Insights
2.
PARP Inhibitors Market Report Introduction
3.
PARP Inhibitors Market Overview at a Glance
4.
PARP Inhibitors Market Executive Summary
5.
Disease Background and Overview
6.
PARP Inhibitors Treatment and Management
7.
PARP Inhibitors Epidemiology and Patient Population
8.
Patient Journey
9.
PARP Inhibitors Marketed Drugs
10.
PARP Inhibitors Emerging Drugs
11.
Seven Major PARP Inhibitors Market Analysis
12.
PARP Inhibitors Market Outlook
13.
Potential of Current and Emerging Therapies
14.
KOL Views
15.
Unmet Needs
16.
SWOT Analysis
17.
Appendix
18.
DelveInsight Capabilities
19.
Disclaimer
20.
About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
